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Abstract 
Cutaneous manifestations can occur in the wide range of internal malignancy. They can 
occur by metastases or local spread, direct infiltration, or a site of primary malignancy itself. 
Sometimes these manifestations are related with an underlying malignancy but they do not 
contain malignant cells as paraneoplastic dermatological syndromes. Chronic lymphocytic 
leukemia (CLL) is the most common leukemia all over the world. Cutaneous lesions occur in 
up to 25% of patients. Most commonly seen cutaneous lesions in CLL are those of infectious 
or hemorrhagic origin. Skin cancer risk was also increased eightfold in CLL when compared 
with normal population, so cutaneous lesions in CLL can be the first manifestation of 
secondary skin malignancy. Herein, we report an interesting case of Kaposi’s sarcoma which 
was diagnosed during the course of CLL. 
 
Introduction 
Kaposi’s sarcoma (KS) is a spindle-cell malignant low-grade vascular tumor 
associated with human herpesvirus 8 (HHV-8) [1]. It was first published by the 
dermatologist Moritz Kaposi in the journal Archiv für Dermatologie und Syphilis, in 1872 
[2]. In the current literature, four main types of KS are described: (1) epidemic or AIDS-
related KS, (2) KS in immunocompromised patients, (3) classic KS, and (4) endemic or 
African KS. All four types are seen more often among men than women [3]. 
Chronic lymphocytic leukemia (CLL) is presented with an increasing number of 
functionally incompetent mature lymphocytes which are of monoclonal origin, mainly  
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in the peripheral blood, bone marrow, and all throughout the reticuloendothelial 
system. CLL is the most common leukemia in Western countries. 
Herein we report an interesting case of KS which was diagnosed during the course of 
CLL as a secondary malignancy. 
Case Report 
A 64-year-old female case presented with complaints of bluish and indurate lesions all over both 
lower extremities (fig. 1). She was first evaluated in a dermatology out-patient clinic. After initial 
evaluation, biopsy was done from the lesions and KS was diagnosed (fig. 2, fig. 3). The case was 
referred to the Medical Oncology Department. The patient has had a history of CLL since the year of 
1999 but she has not needed any active drug treatment since 1999. She did not have any complication 
such as bacterial infection or hemolytic anemia throughout the disease course. There was no risk 
factor in her personal history that disposed the patient to AIDS. Her physical examination revealed 
hepatosplenomegaly and peripheral lymphadenopathy. Her laboratory workup showed marked 
lymphocytosis with mature lymphocytes. Laboratory panels for hepatitis B, C and HIV were negative. 
Quantitative immunoglobulin M and A levels were decreased, whereas immunoglobulin G level was 
normal. Abdominal and thoracic CT scan showed widespread lymphadenopathy with 
hepatosplenomegaly. Endoscopic and colonoscopic evaluation of the gastrointestinal system revealed 
normal findings. Although all tests were negative for systemic involvement of KS, KS lesions have an 
allover pattern in both extremities, so we planned to administer systemic chemotherapy which 
consisted of anthracycline, vincristine, and bleomycine. After three cycles of systemic chemotherapy, 
the lesions had completely disappeared and there was no toxicity of chemotherapeutics. 
Discussion 
Although in the literature, there is a strong relationship between 
immunosuppression after solid organ transplantation and KS, there is no strong data 
that shows a relation between CLL and KS. Patients with CLL are prone to the viral, 
bacterial, and opportunistic infection even without taking any chemotherapeutics. 
Although immunosuppression in CLL can dispose the patient to the infection, can it 
cause tending to the formation of secondary malignancy? Hisada et al. [4] reported that 
KS is 5 times more common in the CLL population than the normal population. In this 
surveillance study about secondary malignancies preceding CLL diagnosis, Hisada et al. 
analyzed 16,367 patients with CLL, so we cannot just say that the increased incidence 
of KS in CLL patients is an incidental finding. Median latency time between diagnosis of 
CLL and preceding KS was 75 months in this unique study [4]. 
Over 90 percent of KS cases are infected and probably caused by HHV-8 infection. It 
is true for all types of KS including AIDS-related KS, KS in immunocompromised 
patients, classic KS and endemic or African KS [1]. Control of HHV-8 infection is 
mediated by an antiviral T-cell response to HHV-8 proteins [5]. The development of KS 
is associated with reactivation of HHV-8 in transplant recipients. Latent HHV-8 
infection of endothelial cells can cause subsequent conversion of endothelial cells into 
the spindle cells. Then the proliferative phase started, and VEGF secretion increased 
from the infected endothelial cells. This activation plays a pivotal role in the 
development of the final tumor [6]. Is this a mechanism that causes KS in CLL patient? 
We know that there is an imbalance in circulating T-cell subpopulations in CLL [7]. So  
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theoretically, latent HHV-8 infection can be reactivated in CLL patients and can trigger 
KS lesions. 
In conclusion, CLL can dispose to the development of KS but the exact mechanism is 
not explained as much as KS preceding solid organ transplantation. So physicians 
should be very careful about the probability of KS in newly and progressively 
developing skin lesions in CLL. 
 
 
 
 
 
 
Fig. 1. Bluish and indurate lesions at the lower extremity of the patient. 
 
 
 
Fig. 2. Nodular lesion composed of vascular spaces and spindle cells (HE, ×100). 
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Fig. 3. Vascular spaces containing erythrocytes. Note the mitosis (encircled) (HE, ×400). 
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